Revenue - Additional Information (Detail) - USD ($)		3 Months Ended			6 Months Ended		12 Months Ended
	May 17, 2024	Dec. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue			$ 9,477,000	$ 9,105,000	$ 21,161,000	$ 16,788,000
Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Product rights agreement, closing date					May 17, 2023
Receipt of upfront license fee					$ 75,000,000
Eyebiotech License Agreement [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment	$ 500,000
Receipt of upfront license fee					500,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment					16,500,000
Revenue			300,000	200,000	600,000	500,000
Deferred revenue, current			1,500,000		1,500,000				$ 1,400,000
Deferred revenue, non-current			11,700,000		11,700,000				$ 12,400,000
RPA [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue				3,200,000
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Revenue			1,100,000	5,300,000	1,700,000	12,700,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue			1,068,000	5,273,000	1,726,000	12,667,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue			500,000	500,000	500,000	500,000
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			600,000		1,200,000
License and Collaboration Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			7,782,000	3,597,000	18,345,000	3,631,000
License and Collaboration Agreement [Member] | Eyebiotech License Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 500,000		500,000
Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Revenue			627,000	235,000	1,090,000	490,000
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue			300,000	$ 0	500,000	0
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment					75,000,000
Deferred revenue, current			31,800,000		31,800,000
Deferred revenue, non-current			0		$ 0
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Guaranteed payments		$ 1,875,000						$ 7,500,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period					2028
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Royalty payments							$ 70,000,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period					2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue			$ 7,100,000		$ 17,500,000	$ 3,200,000
Supply Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Initial term of the supply agreement					2 years
Initial Term of Estimated Supply Units					2 years